Delayed first injection of the once-a-month injectable contraceptive containing 25 mg of medroxyprogesterone acetate and 5 mg of E2-cypionate: Effects on ovarian function

Carlos Alberto Petta, Melissa Hays, Vivian Brache, Rebeca Massai, Yang Hua, Francisco Alvarez-Sánchez, Horacio Croxatto, Catherine D'Arcangues, Lynley A. Cook, Luis Bahamondes

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Objective: To assess whether women who were administered the first injection of DMPA+E2C on day 7 of their menstrual cycle (delayed injection) exhibit the same degree of ovarian suppression as women who receive it on day 5 of their menstrual cycle. Design: Multicenter, randomized controlled trial.Setting: Reproductive health clinics. Patient(s): Women aged between 18 and 38 years (inclusive) willing to use DMPA+E2C as their method of contraception. Intervention(s): Participants received a DMPA+E2C injection on day 5 (control group, n = 41) or day 7 (delayed-injection group, n = 117) of their menstrual cycle. Main Outcome Measure(s): Ovarian activity and follicular development determined by serial serum progesterone levels and vaginal ultrasound. Result(s): Participants who received DMPA+E2C on day 5 of their menstrual cycle (control group) exhibited no more than limited follicular growth (no follicle >16 mm). Of those women who received DMPA+E2C on day 7 of their menstrual cycle (delayed-injection group), 21 (18%) showed some follicular growth, of whom 4 (3%) ovulated. Conclusion(s): The first injection of DMPA+E2C given on day 7 of a menstrual cycle does not provide the same inhibition of ovarian activity as that observed when it is administered on day 5 of the menstrual cycle.

Original languageEnglish
Pages (from-to)744-748
Number of pages5
JournalFertility and Sterility
Volume75
Issue number4
DOIs
Publication statusPublished - 2001

Keywords

  • Contraception
  • Cyclofem
  • Ovulation
  • Progesterone
  • Randomized controlled trial
  • Ultrasound

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Fingerprint

Dive into the research topics of 'Delayed first injection of the once-a-month injectable contraceptive containing 25 mg of medroxyprogesterone acetate and 5 mg of E2-cypionate: Effects on ovarian function'. Together they form a unique fingerprint.

Cite this